Screener
CRISPR Therapeutics CRSP Q2 2026 earnings
Reported August 3, 2026 · After market close
Revenue$10.2MBeat by $2.7M
EPS-$0.94Beat by $0.25
Revenue estimate$7.4M
EPS estimate-$1.19
Next report
Nov 9, 2026 (in 2 months)Revenue estimate$14.8M
EPS estimate-$1.06
Valuation & ratios
Valuation
as of 08/27/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did CRISPR Therapeutics report Q2 2026 earnings?
- CRISPR Therapeutics (CRSP) reported Q2 2026 earnings on August 3, 2026 after market close.
- What were CRISPR Therapeutics's Q2 2026 revenue and EPS?
- CRISPR Therapeutics reported revenue of $10.2M and eps of $-0.94 for Q2 2026.
- Did CRISPR Therapeutics beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $7.4M by $2.7M. EPS beat the consensus estimate of $-1.19 by $0.25.
- How did CRISPR Therapeutics's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 1041.4% from $892.0K a year earlier and eps grew 27.1% from $-1.29.
- Where can I find CRISPR Therapeutics's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-330644) and the 10-Q periodic report (0001193125-26-330672) directly on SEC EDGAR. The filing index links above go to sec.gov.
